Syngene International Extends Strategic Bristol Myers Squibb Collaboration Through 2035
核心洞察
Syngene International (搜索) has extended its strategic research collaboration with Bristol Myers Squibb (搜索) through 2035, marking over 25 years of partnership in drug development.
The expanded agreement broadens integrated services across the entire drug development lifecycle, from discovery through commercialization, including chemistry, biology, clinical trials, and manufacturing.
The collaboration centers around the Biocon Bristol Myers Squibb Research and Development Center (搜索), which houses approximately 700 Syngene scientists working across cardiovascular (搜索), fibrosis (搜索), immunology (搜索), and oncology (搜索) therapeutic areas.
Syngene International (搜索), a global contract research, development, and manufacturing organization (CRDMO), has announced the extension of its strategic collaboration with Bristol Myers Squibb (搜索) through 2035, expanding a partnership that has spanned more than 25 years in pharmaceutical research and development.
Comprehensive Drug Development Services
The expanded agreement significantly broadens the scope of integrated services across the entire drug development lifecycle. The collaboration now encompasses discovery services including chemistry and biology, drug metabolism and pharmacokinetics, translational sciences, pharmaceutical development and manufacturing, clinical trials, and data and information technology services. This comprehensive approach enables seamless progression from research to commercialization.
According to Peter Bains, Managing Director and CEO of Syngene International (搜索) Ltd., "Our collaboration with Bristol Myers Squibb (搜索), which now spans more than 25 years, is anchored in scientific excellence, operational reliability, and a shared commitment to advancing innovative therapies."
Strategic Research Center Operations
The partnership centers around the Biocon Bristol Myers Squibb Research and Development Center (搜索) (BBRC), which was established following the initial collaboration in 1998 and fully commissioned in 2009. The BBRC has evolved into a major strategic R&D site for Bristol Myers Squibb (搜索), supporting integrated capabilities across target identification, lead discovery, lead optimization, pharmaceutical development, molecular and cell biology, protein sciences, assay biology and clinical biomarkers.
The center currently houses approximately 700 Syngene scientists who work as an extension of Bristol Myers Squibb (搜索)'s global research organization. These scientists contribute to discovery, preclinical development, and patent filings across multiple therapeutic areas including cardiovascular (搜索), fibrosis (搜索), immunology (搜索), and oncology (搜索).
Impact on Drug Development Timeline
Since its inception, the BBRC has played a pivotal role in accelerating the progression of novel compounds from early discovery to first-in-human studies, thereby helping reduce development timelines and overall costs for Bristol Myers Squibb (搜索). This integrated approach has demonstrated the value of long-term strategic partnerships in pharmaceutical research and development.
Payal Sheth, Senior Vice President, Therapeutic Discovery Sciences at Bristol Myers Squibb (搜索), emphasized the partnership's patient-focused mission: "At Bristol Myers Squibb, everything we do begins with patients. We greatly value our long-standing partnership with Syngene, which has been instrumental in advancing our scientific ambitions."
The extension of this collaboration through 2035 reinforces Syngene's position as a strategic partner delivering integrated, end-to-end scientific and manufacturing solutions in the pharmaceutical industry.